- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06294509
taVNS Application Timing During Robotic Sensorimotor Task (SMTaVNS2024)
Feasibility and Effects of Transcutaneous Auricular Vagus Nerve Stimulation Timings in a Sensorimotor Task
The goal of this clinical trial is to evaluate the feasibility and effectiveness of transcutaneous auricular vagus nerve stimulation (taVNS) in enhancing sensorimotor learning and adaptation. This study will focus on healthy individuals performing a robotic sensorimotor task.
Main Questions it Aims to Answer:
How does taVNS, with different timing protocols, affect the feasibility and effectiveness of performing a robotic sensorimotor task? What is the impact of taVNS on sensorimotor learning and adaptation?
Participants Will:
Be pseudo-randomly assigned to one of five experimental groups with different taVNS stimulation timings.
Perform a sensorimotor task multiple times across sessions, spanning a maximum of two weeks or until achieving 70% accuracy in two successive sessions.
Have kinematic data collected by a robot during the task. Have physiological data measured using external sensors. Fill out questionnaires about the feasibility of taVNS and other subjective measures after each session.
Comparison Group:
Researchers will compare the four experimental groups to each other to see if different taVNS stimulation timings affect sensorimotor learning outcomes, as well as to a control group that will receive no stimulation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overview:
This study focuses on the potential of transcutaneous auricular Vagus Nerve Stimulation (taVNS) in motor neurorehabilitation for conditions like Parkinson's disease, traumatic brain injury, spinal cord injury, and stroke. taVNS, approved for various neurological conditions and known for its safety, activates neuromodulators contributing to plasticity and motor learning. However, the optimal stimulation parameters, especially timing during movement, are not fully explored.
Study Goals:
Primary Objective: To assess the feasibility and effects of different taVNS timing protocols in a robotic sensorimotor task on sensorimotor learning and adaptation. The hypothesis is that varying taVNS-movement timings will influence both subjective and objective feasibility measures and sensorimotor adaptation.
Secondary Objectives: To compare movement kinematics and contrast perceived stimulation effects with measured physiological outcomes and task performance metrics.
Methodology:
The study will be conducted at Swiss Federal Institute of Technology (ETH) Zurich with healthy subjects using a robotic sensorimotor task to evaluate the feasibility of movement-timed taVNS and its influence on learning new sensorimotor skills.
Participants will be assigned different stimulation timings, with the study assessing motor learning and performance consistency across a maximum of 6 sessions or until 70% success is reached in two successive sessions.
The study design is single-blinded, pseudo-randomized, exploratory, and longitudinal, employing controls like no stimulation and randomly-timed stimulation.
Intervention Details:
Before each session, two electrodes (e.g. TensCare pads) will be connected to the pulse generator and 1) placed on the cymbae conchae of the ear and 2) on the tragus of the ear, allowing for a previously described taVNS biphasic pulse train to travel. Here, biphasic square pulses of 250ms width are sent at 25 Hertz (Hz) frequency for 0.5s at a maximum aptitude of 3 milliamperes (mA). The stimulation pulses are current-controlled, limited to 50 Volts (V) and regulated by a pulse generator that limits deliverable current in hardware by design with serial resistors and diodes.
At the start of the session, participants will use a python graphical user interface (GUI) to calibrate the desired taVNS amplitude by gradually increasing it from minimal 0.1 mA up to the maximal tolerated amplitude below 3 mA in the intervals of 0.1 mA. The level of intensity will be set to 90% of the maximally tolerated amplitude for the person (typical ~1.5-2 mA & limited to 3mA, which is significantly below the safety limit of 50mA (according to the Product Safety Standards for Medical Devices, IEC 60601-2-10:2012). This procedure takes 1-2 min. Following the calibration, the session with the sensorimotor task will begin.
Sensorimotor task The sensorimotor task utilizes a commercial haptic end effector (Touch, 3D systems), a custom made 3D printed handle and a virtual reality environment, implemented in python and PsychoPy software on a Microsoft Windows laptop. The robotic manipulandum is synchronized to a 1cm circular cursor in the workspace of the virtual environment. Additionally, an arm-support (SaeboMas Mini) is used to support the arm against gravity to reduce fatigue and keep the arm in the correct position - elbow is 90 degrees perpendicular to the ground.
The goal of the sensorimotor task is to reach a 2.4cm target at a distance of 10 cm away from a starting position, both visually represented in the virtual environment. In order to successfully complete a trial the participant must reach the target within a time constraint of 0.5 s +/- 0.067 s. There will be a 0.5 s tone sound notifying the target duration of the movement. During this movement the cursor position is hidden and not displayed on the screen (in perturbation and retention phases) in order to force feedforward motor adaptation, rather than visually-guided feedback control, as feedforward adaptation may be impaired in stroke patients. Results of each trial are displayed as 3 distinct possibilities - correct, target reached too quickly, or target not reached. The subject will be notified of the outcome of the trial by the target turning either, green, orange or red respectively. Afterwards the start location will be displayed for the participant to return to. After 1-3 s within the starting point a new trial will be initiated.
Participants will perform 75 baseline trials (no visuomotor rotation) to get familiar with the robotic manipulandum and the environment. Then participants will perform an additional 150 trials in the challenged condition with a virtual rotational field (visuomotor rotation/perturbation), displayed on the screen. Subjects will not be informed about the nature of the sensorimotor challenge and will have to progressively learn the corrective mapping to adapt to the perturbation. No external forces will be applied and the haptic end-effector is solely used to measure handle end-point kinematics. Then subjects will perform 50 trials of the same baseline trials (wash-out) and finally 50 more trials of the rotational field (retention). The time requirement is expected to be 5-10 min for the setup and explanations and ~30 min for the sensorimotor task. Data from each trial will be stored containing the position of the cursor, success/fail and time information for subsequent analysis. Additional movement kinematic data may be collected using inertial measurement unit (IMU) sensors worn on the wrist. The IMU records acceleration and gyroscope measurements and logs data to the experimental computer at a rate of 120Hz. Additionally all data pertaining to stimulation will be stored, this includes timing, impedance measurements and all communication commands to and from the stimulator.
Research Significance:
The findings could inform future clinical studies in neurorehabilitation. The study uses a "Touch™" haptic device for the task, ensuring participant safety and comfort.
Potential side effects of taVNS are minimal and closely monitored.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Paulius Viskaitis, PhD
- Phone Number: +41 76 645 61 80
- Email: paulius.viskaitis@hest.ethz.ch
Study Contact Backup
- Name: Olivier Lambercy, Prof PhD
- Phone Number: +41 44 632 71 66
- Email: olivier.lambercy@hest.ethz.ch
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy participants above 18 years of age and able to provide informed consent and understand the study requirements
Exclusion Criteria:
- Individuals with major untreated depression, major cognitive and/or communication deficits, and major comprehension and/or memory deficits that may interfere with the informed consent process, task-specific practice, or communication of adverse events will be excluded from the study.
- Neurological conditions such as epilepsy, participation in any other research trial, pregnancy, use of implanted electrical devices, and use of medication or procedure that interferes with vagal functions.
- Pregnancy or trying to get pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No stimulation (control)
Participants will wear device but will not receive any stimulation
|
|
Active Comparator: Movement-unrelated stimulation (control)
Participants will wear device and receive randomly timed stimulation
|
taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus.
The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation.
Before each session, taVNS is calibrated for each participant.
Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached.
Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train.
Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation.
Participants adapt their movements over up to six sessions across two weeks.
The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
|
Experimental: pre-movement taVNS
Stimulation will start after 500ms of being in the home position, before the onset of the movement cue.
|
taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus.
The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation.
Before each session, taVNS is calibrated for each participant.
Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached.
Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train.
Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation.
Participants adapt their movements over up to six sessions across two weeks.
The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
|
Experimental: during-movement taVNS
Stimulation will occur during the movement phase.
|
taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus.
The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation.
Before each session, taVNS is calibrated for each participant.
Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached.
Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train.
Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation.
Participants adapt their movements over up to six sessions across two weeks.
The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
|
Experimental: post-movement taVNS
Stimulation will occur immediately after a successful trial (no stimulation if the trial is failed).
|
taVNS in this study involves short electric pulses (0.25 ms) delivered to the ear's skin to activate the auricular branch of the Vagus.
The pulses are current-controlled to ensure stability and delivered in a bipolar fashion to prevent skin irritation.
Before each session, taVNS is calibrated for each participant.
Starting at 0.1 mA, the intensity is increased stepwise until a comfortable maximum (typically 1.5-2.5 mA) is reached.
Stimuli are delivered in short trains lasting 0.5 seconds each, with 13 pulses (0.25ms each) per train.
Participants receive a maximum of 150 stimuli per session, totaling a maximum of 75 seconds of cumulative stimulation.
Participants adapt their movements over up to six sessions across two weeks.
The robotic task facilitates accurate movement tracking and provides interactive real-time feedback.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjectively perceived tolerance of taVNS and perceived difficulty of motor task
Time Frame: From enrollment to end of study at 2 weeks
|
The subjective perceived feasibility of the taVNS stimulation paradigm, perceived difficulty level of the task, assessed by an unvalidated questionnaire on the Likert scale.
|
From enrollment to end of study at 2 weeks
|
Success of the sensorimotor challenge
Time Frame: After the intervention
|
Measured as % of trials where the end-point reaching target (2.4 cm diameter) was reached within an allocated time period (0.5 s +/- 0.067 s).
|
After the intervention
|
Mean Change from Baseline in Galvanic Skin Response (GSR)
Time Frame: During and immediately after taVNS
|
Physiological dose response to the taVNS using GSR as indicator
|
During and immediately after taVNS
|
Mean Change from Baseline in Heart Rate (HR)
Time Frame: During and immediately after taVNS
|
Physiological dose response to the taVNS using HR as indicator
|
During and immediately after taVNS
|
Mean Change from Baseline in Pupil Diameter (PD)
Time Frame: During and immediately after taVNS
|
Physiological dose response to the taVNS using PD as indicator
|
During and immediately after taVNS
|
Mean Change from Baseline in electroencephalogram (EEG)
Time Frame: During and immediately after taVNS
|
Physiological dose response to the taVNS using EEG as indicator
|
During and immediately after taVNS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjectively perceived positive effects of taVNS on motor performance
Time Frame: After each session, from enrollment to end of treatment at 2 weeks
|
Subjectively perceived success during taVNS and perceived effects of the taVNS stimulation during the task, assessed by an unvalidated questionnaire on the Likert scale.
|
After each session, from enrollment to end of treatment at 2 weeks
|
Change of movement parameters from baseline
Time Frame: After each session, from enrollment to end of study at 2 weeks
|
Movement kinematics, as recorded by robotic sensors, will be analyzed to assess quantitative properties of the movements.
For example, mean velocity, smoothness of acceleration and trajectory
|
After each session, from enrollment to end of study at 2 weeks
|
Associations between outcomes
Time Frame: upon completion of study, at 2 weeks
|
Association between subjective and objective feasibility measures will be analyzed using multiple way ANOVA tests for each of the measures
|
upon completion of study, at 2 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Rong P, Liu J, Wang L, Liu R, Fang J, Zhao J, Zhao Y, Wang H, Vangel M, Sun S, Ben H, Park J, Li S, Meng H, Zhu B, Kong J. Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: A nonrandomized controlled pilot study. J Affect Disord. 2016 May;195:172-9. doi: 10.1016/j.jad.2016.02.031. Epub 2016 Feb 10.
- Izawa J, Shadmehr R. Learning from sensory and reward prediction errors during motor adaptation. PLoS Comput Biol. 2011 Mar;7(3):e1002012. doi: 10.1371/journal.pcbi.1002012. Epub 2011 Mar 10.
- Badran BW, Peng X, Baker-Vogel B, Hutchison S, Finetto P, Rishe K, Fortune A, Kitchens E, O'Leary GH, Short A, Finetto C, Woodbury ML, Kautz S. Motor Activated Auricular Vagus Nerve Stimulation as a Potential Neuromodulation Approach for Post-Stroke Motor Rehabilitation: A Pilot Study. Neurorehabil Neural Repair. 2023 Jun;37(6):374-383. doi: 10.1177/15459683231173357. Epub 2023 May 20.
- Kim AY, Marduy A, de Melo PS, Gianlorenco AC, Kim CK, Choi H, Song JJ, Fregni F. Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. Sci Rep. 2022 Dec 21;12(1):22055. doi: 10.1038/s41598-022-25864-1.
- Baig SS, Kamarova M, Bell SM, Ali AN, Su L, Dimairo M, Dawson J, Redgrave JN, Majid A. tVNS in Stroke: A Narrative Review on the Current State and the Future. Stroke. 2023 Oct;54(10):2676-2687. doi: 10.1161/STROKEAHA.123.043414. Epub 2023 Aug 30.
- Branscheidt M, Hadjiosif AM, Anaya MA, Keller J, Widmer M, Runnalls KD, Luft AR, Bastian AJ, Krakauer JW, Celnik PA. Reinforcement Learning Is Impaired in the Sub-acute Post-stroke Period. bioRxiv [Preprint]. 2023 Jan 25:2023.01.25.525408. doi: 10.1101/2023.01.25.525408.
- Dietrich S, Smith J, Scherzinger C, Hofmann-Preiss K, Freitag T, Eisenkolb A, Ringler R. A novel transcutaneous vagus nerve stimulation leads to brainstem and cerebral activations measured by functional MRI. Biomed Tech (Berl). 2008 Jun;53(3):104-11. doi: 10.1515/BMT.2008.022.
- Breton-Provencher V, Drummond GT, Sur M. Locus Coeruleus Norepinephrine in Learned Behavior: Anatomical Modularity and Spatiotemporal Integration in Targets. Front Neural Circuits. 2021 Jun 7;15:638007. doi: 10.3389/fncir.2021.638007. eCollection 2021.
- Gielow MR, Zaborszky L. The Input-Output Relationship of the Cholinergic Basal Forebrain. Cell Rep. 2017 Feb 14;18(7):1817-1830. doi: 10.1016/j.celrep.2017.01.060.
- Morrison RA, Hulsey DR, Adcock KS, Rennaker RL 2nd, Kilgard MP, Hays SA. Vagus nerve stimulation intensity influences motor cortex plasticity. Brain Stimul. 2019 Mar-Apr;12(2):256-262. doi: 10.1016/j.brs.2018.10.017. Epub 2018 Nov 3.
- Rodenkirch C, Carmel JB, Wang Q. Rapid Effects of Vagus Nerve Stimulation on Sensory Processing Through Activation of Neuromodulatory Systems. Front Neurosci. 2022 Jul 5;16:922424. doi: 10.3389/fnins.2022.922424. eCollection 2022.
- Bowles S, Hickman J, Peng X, Williamson WR, Huang R, Washington K, Donegan D, Welle CG. Vagus nerve stimulation drives selective circuit modulation through cholinergic reinforcement. Neuron. 2022 Sep 7;110(17):2867-2885.e7. doi: 10.1016/j.neuron.2022.06.017. Epub 2022 Jul 19.
- Donegan D, Kanzler CM, Buscher J, Viskaitis P, Bracey EF, Lambercy O, Burdakov D. Hypothalamic Control of Forelimb Motor Adaptation. J Neurosci. 2022 Aug 10;42(32):6243-6257. doi: 10.1523/JNEUROSCI.0705-22.2022. Epub 2022 Jul 5.
- Wickens JR, Reynolds JN, Hyland BI. Neural mechanisms of reward-related motor learning. Curr Opin Neurobiol. 2003 Dec;13(6):685-90. doi: 10.1016/j.conb.2003.10.013.
- Donegan D, Peleg-Raibstein D, Lambercy O, Burdakov D. Anticipatory countering of motor challenges by premovement activation of orexin neurons. PNAS Nexus. 2022 Oct 25;1(5):pgac240. doi: 10.1093/pnasnexus/pgac240. eCollection 2022 Nov.
- Kanzler CM, Averta G, Schwarz A, Held JPO, Gassert R, Bicchi A, Santello M, Lambercy O, Bianchi M. A low-dimensional representation of arm movements and hand grip forces in post-stroke individuals. Sci Rep. 2022 May 9;12(1):7601. doi: 10.1038/s41598-022-11806-4.
- Lerman I, Davis B, Huang M, Huang C, Sorkin L, Proudfoot J, Zhong E, Kimball D, Rao R, Simon B, Spadoni A, Strigo I, Baker DG, Simmons AN. Noninvasive vagus nerve stimulation alters neural response and physiological autonomic tone to noxious thermal challenge. PLoS One. 2019 Feb 13;14(2):e0201212. doi: 10.1371/journal.pone.0201212. eCollection 2019.
- Mridha Z, de Gee JW, Shi Y, Alkashgari R, Williams J, Suminski A, Ward MP, Zhang W, McGinley MJ. Graded recruitment of pupil-linked neuromodulation by parametric stimulation of the vagus nerve. Nat Commun. 2021 Mar 9;12(1):1539. doi: 10.1038/s41467-021-21730-2.
- Machetanz K, Berelidze L, Guggenberger R, Gharabaghi A. Transcutaneous auricular vagus nerve stimulation and heart rate variability: Analysis of parameters and targets. Auton Neurosci. 2021 Dec;236:102894. doi: 10.1016/j.autneu.2021.102894. Epub 2021 Oct 12.
- Lloyd B, Wurm F, de Kleijn R, Nieuwenhuis S. Short-term transcutaneous vagus nerve stimulation increases pupil size but does not affect EEG alpha power: A replication of Sharon et al. (2021, Journal of Neuroscience). Brain Stimul. 2023 Jul-Aug;16(4):1001-1008. doi: 10.1016/j.brs.2023.06.010. Epub 2023 Jun 20.
- Badran BW, Yu AB, Adair D, Mappin G, DeVries WH, Jenkins DD, George MS, Bikson M. Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): Technique, Targeting, and Considerations. J Vis Exp. 2019 Jan 7;(143):10.3791/58984. doi: 10.3791/58984.
- Kaniusas E, Kampusch S, Tittgemeyer M, Panetsos F, Gines RF, Papa M, Kiss A, Podesser B, Cassara AM, Tanghe E, Samoudi AM, Tarnaud T, Joseph W, Marozas V, Lukosevicius A, Istuk N, Lechner S, Klonowski W, Varoneckas G, Szeles JC, Sarolic A. Current Directions in the Auricular Vagus Nerve Stimulation II - An Engineering Perspective. Front Neurosci. 2019 Jul 24;13:772. doi: 10.3389/fnins.2019.00772. eCollection 2019.
- Dabiri B, Zeiner K, Nativel A, Kaniusas E. Auricular vagus nerve stimulator for closed-loop biofeedback-based operation. Analog Integr Circuits Signal Process. 2022;112(2):237-246. doi: 10.1007/s10470-022-02037-8. Epub 2022 May 10.
- Joshi S, Li Y, Kalwani RM, Gold JI. Relationships between Pupil Diameter and Neuronal Activity in the Locus Coeruleus, Colliculi, and Cingulate Cortex. Neuron. 2016 Jan 6;89(1):221-34. doi: 10.1016/j.neuron.2015.11.028. Epub 2015 Dec 17.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SMTaVNS 2024
- 2024-00039 (Registry Identifier: BASEC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on in-house developed transcutaneous auricular Vagus Nerve Stimulation device
-
Jiani WuNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityBrainClos Co., LTD.; Zhuhai Fudan Innovation InstituteNot yet recruitingCluster Headache | Migraine in Children | Tension Headache | Migraine in Adolescence | Primary HeadacheChina
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingParkinson DiseaseChina
-
Sahlgrenska University Hospital, SwedenRecruitingBorderline Personality DisorderSweden
-
Cairo UniversityRecruitingStroke | Motor DisordersEgypt
-
University of MiamiRecruiting
-
Guang'anmen Hospital of China Academy of Chinese...China Association for Science and TechnologyRecruiting
-
University Hospital TuebingenUniversität TübingenCompleted
-
Northwell HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingFocal Segmental Glomerulosclerosis | Minimal Change Disease | Nephrotic Syndrome in ChildrenUnited States